Hydroxychloroquine relative bioavailability: Within subject reproducibility

British Journal of Clinical Pharmacology

Volumn 41, Issue 3, 1996, Pages 244-246

  Tett, Susan ^a,b,c,d   Day, Richard ^a,b   Cutler, David ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Bioavailability; Hydroxychloroquine

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSOLUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET;

EID: 0029871140     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00190.x     Document Type: Article

References (8)

1. Tett S. Clinical pharmacokinetics of slow acting antirheumatic drugs. Clin Pharmacokinet 1993; 25: 392-407.
2. Tett SE, Day RO, Cutler DJ. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis - a cross-sectional study. J Rheumatol 1993; 20: 1874-1879.
3. Tett SE, Cutler DJ, Brown KF. High-performance liquid chromatography assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of polystyrene divinylbenzene) and a mobile phase at pH 11, with fluorimetric detection. J Chromatogr 1985; 344: 241-8.
4. Tett SE, Cutler DJ, Day RO. Bioavailability of hydroxychloroquine assessed using deconvolution techniques. J Pharm Sci 1992; 81: 155-159.
5. Urso R, Aarons L. Bioavailability of drugs with long elimination half-lives. Eur J Clin Pharmacol 1983; 25: 689-693.
6. Lovering EG, McGilveray IJ, McMilland I, Tostowaryk W. Comparative bioavailabilities from truncated blood level curves. J Pharm Sci 1975; 64: 1521-1524.
7. Wijnand HP. The determination of the absolute bioavailability for drug substances with long elimination half-lives (with PC-programs for the method of truncated areas). Comp Methods Progr Biomed 1992; 39: 61-73.
8. Karlsson MO, Sheiner LB. The importance of modelling interoccasion variability in population pharmacokinetics analyses. J Pharmacokin Biopharm 1993; 21: 735-750.